EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Immune Modulation Related to High-Dose Valacyclovir Administration for Primary Cytomegalovirus Infection in Pregnancy: An Insight into Virus Behavior and Maternal Serology

Marco De Santis, Silvio Tartaglia iD, Chiara Cerra, Daniela Visconti, Piero Valentini iD, Antonio Lanzone, Lucia Masini, Rosaria Santangelo

Viruses · 2025

DOI: 10.3390/v17020157 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Viruses, 2025. Verfasst von Marco De Santis und 7 weiteren Autor:innen. Beteiligte Einrichtung: Ostetricia e Patologia Ostetrica, Dipartimento di Scienze della Salute della Donna, Fondazione Policlinico Universitario A. Gemelli IRCCS, del Bambin…. Hauptthemen laut MEDLINE: Valacyclovir, Cytomegalovirus Infections, Antiviral Agents, Pregnancy Complications, Infectious. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cytomegalovirus (CMV) infection during pregnancy poses significant maternal and fetal health risks. Valacyclovir, an antiviral drug, has been explored as a therapeutic option for managing primary CMV infections in pregnant women. This study investigates the effects of valacyclovir therapy on immune response maturation against CMV, maternal antibody levels, and viral replication during treatment. We conducted a retrospective observational study involving pregnant women diagnosed with primary CMV infection and presenting in utero infection who received high-dose valacyclovir therapy (8 g/day). A group started the therapy at diagnosis, while another group started only after positive amniocentesis. Maternal antibody levels (IgM, IgG, and IgG avidity) and PCR for CMV testing (in blood, urine, and saliva) were measured longitudinally during the second and third trimesters. Our findings indicate that early valacyclovir therapy is related to lower avidity levels over time and a delay in reaching a high IgG avidity level (18.22 ± 1.21 weeks) compared to the patients who started Valacyclovir during the second trimester after positive amniocentesis (14.52 ± 1.64 weeks; p = 0.066). The therapy does not condition the overall concentration of maternal CMV-specific IgM and IgG. While high-dose VCV does not directly target the mechanism of IgG avidity maturation, it can interfere with this process by reducing the viral load and antigen presentation, influencing IgG avidity maturation. Further research is needed to elucidate the long-term implications of potential immunological modulation induced by Valacyclovir and to optimize early diagnosis and the right treatment protocol during pregnancy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ValacyclovirCytomegalovirus InfectionsAntiviral AgentsPregnancy Complications, InfectiousCytomegalovirusHumansFemalePregnancyRetrospective StudiesAdultAntibodies, ViralImmunoglobulin GImmunoglobulin MYoung Adult

Stichwörter der Autor:innen

IgG aviditycytomegalovirusimmune systempregnancyvalacyclovir

Substanzen

ValacyclovirAntiviral AgentsAntibodies, ViralImmunoglobulin GImmunoglobulin M

Autor:innen und Institutionen

  • Ostetricia e Patologia Ostetrica, Dipartimento di Scienze della Salute della Donna, Fondazione Policlinico Universitario A. Gemelli IRCCS, del Bambino e di Sanità Pubblica, 00168 Rome, Italy.
  • Istituto di Clinica Ostetrica e Ginecologica, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
  • Center for Fetal Care and High-Risk Pregnancy, Department of Obstetrics and Gynecology, University "G. D'Annunzio", 66013 Chieti, Italy.
  • Pediatria, Dipartimento di Scienze della Salute della Donna, Fondazione Policlinico Universitario A. Gemelli IRCCS, del Bambino e di Sanità Pubblica, 00168 Rome, Italy.
  • Istituto di Clinica Pediatrica, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
  • UOC di Microbiologia, Dipartimento di Scienze di Laboratorio e Ematologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.

ORCID-Profile: Silvio Tartaglia, Piero Valentini

Zitieren

APA

De Santis, M., Tartaglia, S., Cerra, C., Visconti, D., Valentini, P., Lanzone, A., Masini, L., & Santangelo, R. (2025). Immune Modulation Related to High-Dose Valacyclovir Administration for Primary Cytomegalovirus Infection in Pregnancy: An Insight into Virus Behavior and Maternal Serology. Viruses. https://doi.org/10.3390/v17020157

Vancouver

De Santis M, Tartaglia S, Cerra C, Visconti D, Valentini P, Lanzone A, et al. Immune Modulation Related to High-Dose Valacyclovir Administration for Primary Cytomegalovirus Infection in Pregnancy: An Insight into Virus Behavior and Maternal Serology. Viruses. 2025. doi:10.3390/v17020157

BibTeX
@article{DeSantis2025,
  author = {De Santis, Marco and Tartaglia, Silvio and Cerra, Chiara and Visconti, Daniela and Valentini, Piero and Lanzone, Antonio and Masini, Lucia and Santangelo, Rosaria},
  title = {Immune Modulation Related to High-Dose Valacyclovir Administration for Primary Cytomegalovirus Infection in Pregnancy: An Insight into Virus Behavior and Maternal Serology},
  journal = {Viruses},
  year = {2025},
  doi = {10.3390/v17020157}
}
Kostenlos starten →